Cargando…
Coronavirus disease 2019 (COVID-19): first indication of efficacy of Gene-Eden-VIR/Novirin in SARS-CoV-2 infection
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier B.V. and International Society of Chemotherapy.
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7146686/ https://www.ncbi.nlm.nih.gov/pubmed/32283177 http://dx.doi.org/10.1016/j.ijantimicag.2020.105971 |
| _version_ | 1783520258651324416 |
|---|---|
| author | Polansky, Hanan Lori, Gillad |
| author_facet | Polansky, Hanan Lori, Gillad |
| author_sort | Polansky, Hanan |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7146686 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | Elsevier B.V. and International Society of Chemotherapy. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-71466862020-04-10 Coronavirus disease 2019 (COVID-19): first indication of efficacy of Gene-Eden-VIR/Novirin in SARS-CoV-2 infection Polansky, Hanan Lori, Gillad Int J Antimicrob Agents Article Elsevier B.V. and International Society of Chemotherapy. 2020-06 2020-04-10 /pmc/articles/PMC7146686/ /pubmed/32283177 http://dx.doi.org/10.1016/j.ijantimicag.2020.105971 Text en © 2020 Elsevier B.V. and International Society of Chemotherapy. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Article Polansky, Hanan Lori, Gillad Coronavirus disease 2019 (COVID-19): first indication of efficacy of Gene-Eden-VIR/Novirin in SARS-CoV-2 infection |
| title | Coronavirus disease 2019 (COVID-19): first indication of efficacy of Gene-Eden-VIR/Novirin in SARS-CoV-2 infection |
| title_full | Coronavirus disease 2019 (COVID-19): first indication of efficacy of Gene-Eden-VIR/Novirin in SARS-CoV-2 infection |
| title_fullStr | Coronavirus disease 2019 (COVID-19): first indication of efficacy of Gene-Eden-VIR/Novirin in SARS-CoV-2 infection |
| title_full_unstemmed | Coronavirus disease 2019 (COVID-19): first indication of efficacy of Gene-Eden-VIR/Novirin in SARS-CoV-2 infection |
| title_short | Coronavirus disease 2019 (COVID-19): first indication of efficacy of Gene-Eden-VIR/Novirin in SARS-CoV-2 infection |
| title_sort | coronavirus disease 2019 (covid-19): first indication of efficacy of gene-eden-vir/novirin in sars-cov-2 infection |
| topic | Article |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7146686/ https://www.ncbi.nlm.nih.gov/pubmed/32283177 http://dx.doi.org/10.1016/j.ijantimicag.2020.105971 |
| work_keys_str_mv | AT polanskyhanan coronavirusdisease2019covid19firstindicationofefficacyofgeneedenvirnovirininsarscov2infection AT lorigillad coronavirusdisease2019covid19firstindicationofefficacyofgeneedenvirnovirininsarscov2infection |